Biotech: Page
-
Former Editas CEO Bosley joins UK venture capital firm
Bosley, who once led the CRISPR gene editing biotech, will become a venture partner at Advent Life Sciences, which backs a range of early-stage drug companies.
By Ned Pagliarulo • May 26, 2022 -
A cash-strapped biotech winds down operations
With the market for biotech stocks constrained, Genocea Biosciences plans to delist from Nasdaq and lay off the its remaining employees.
By Kristin Jensen • May 25, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Responding to outbreak, Moderna starts early work on monkeypox vaccine
One day after the U.S. began releasing supplies of an approved Bavarian Nordic shot, Moderna said it's beginning development of its own vaccine against the virus.
By Jonathan Gardner • May 24, 2022 -
Springworks shares fall despite drug trial's success
The biotech plans to seek FDA approval for its soft-tissue tumor treatment after positive study results. But investors still sent the stock down by nearly 10%.
By Ned Pagliarulo • May 24, 2022 -
Elizabeth Regan/BioPharma Dive
Concert drug helps regrow hair in study, boosting shares
There are no treatments specifically approved for alopecia areata. Concert follows Pfizer and Eli Lilly in reporting positive late-stage results for drugs the companies are developing for the autoimmune disorder.
By Ned Pagliarulo • May 23, 2022 -
Getty Images
Sponsored by GoodRxCommon barriers to patient engagement: What's your strategy?
As with treatment, and even adherence, there is no 'one size fits all' when it comes to patient engagement.
May 23, 2022 -
Getty / Edited by BioPharma Dive
PTC's first gene therapy gains European regulator's backing
The brain-infused treatment for a rare neurological disease would be one of only three gene therapies commercially available in the EU. PTC plans to ask for FDA approval later this year.
By Jonathan Gardner • May 20, 2022 -
National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
Trial setback casts doubt on a biotech's respiratory virus drug
As vaccines for respiratory syncytial virus progressed, Enanta used its hepatitis C know-how to develop an antiviral pill. Yet data in lower-risk patients raise questions of whether it can work.
By Jonathan Gardner • May 19, 2022 -
Permission granted by Odyssey Therapeutics
Cancer drug startup draws former Vertex CEO to board
Jeffrey Leiden will team up again with biotech entrepreneur Gary Glick, this time as board chairman of Glick's new company, the recently launched Odyssey Therapeutics.
By Kristin Jensen • May 19, 2022 -
Courtesy of Vertex Pharmaceuticals
Vertex adds to Boston expansion with plans for new site
The addition, which will be located next to the company's newly dedicated cell and gene facility, could make Vertex the largest biotech by square footage in the city.
By Kristin Jensen • May 18, 2022 -
Getty Images
Moderna may seek to claw back payments to ex-CFO
Jorge Gomez, who lasted one day on the job before being ousted over an investigation at his former company, is owed $700,000 — money Moderna says it can recoup if wrongdoing is proven.
By Maura Webber Sadovi • May 17, 2022 -
Danielle Ternes/BioPharma Dive
Gene therapy safetyScientists home in on cause of Duchenne gene therapy side effect
An unusual collaboration among gene therapy developers suggests certain mutations could be behind "peculiar" side effects experienced by several patients treated in clinical trials.
By Jonathan Gardner • Updated May 18, 2022 -
Jonathan Gardner/BioPharma Dive
Agios to cut jobs as it moves away from exploratory research
The biotech expects that, by keeping its focus on more advanced projects and clinical programs, it could save on average $40 million to $50 million annually for the next several years
By Jacob Bell • May 16, 2022 -
Dimitrios Kambouris / Getty Images for Gabrielle's Angel Foundation via Getty Images
Seagen CEO Siegall resigns amid domestic violence investigation
The biotech company is searching for a permanent successor to Clay Siegall, who was arrested last month for alleged domestic violence. CMO Roger Dansey will continue as interim CEO.
By Ben Fidler • Updated May 16, 2022 -
Getty Images
Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug
The deal hands $275 million upfront to Cullinan, whose medicine is being developed for a genetic driver of lung tumors that's become a top target for drugmakers.
By Kristin Jensen • May 12, 2022 -
Getty Images
Moderna's finance head is out as former employer conducts investigation
Jorge Gomez, who officially took the CFO reins Monday, lasted one day on the job. His departure comes as Gomez's previous company, Dentsply Sirona, looks into financial allegations against current and former executives.
By Jacob Bell • May 11, 2022 -
Permission granted by Sekar Kathiresan
In first, Verve gets clearance to test base editing inside the body
Regulators in New Zealand have allowed human testing to proceed, another milestone for the gene editing technology. Verve plans to soon ask for approval to begin testing in the U.S. and U.K., too.
By Kristin Jensen • May 11, 2022 -
Permission granted by Moma Therapeutics
Against a historic market downturn, Moma Therapeutics raises $150M for precision cancer research
The biotech's Series B round, which kicked off early this year, should fund its work on "molecular machines" until at least 2024, according to CEO Asit Parikh.
By Jacob Bell • May 10, 2022 -
Former Novartis exec joins ADC Therapeutics as CEO after brief stint as Rafael head
Ameet Mallik takes over for founder Chris Martin at helm of the antibody drug developer after a seven-month run leading Rafael Holdings, which reported a clinical trial setback last October.
By Ned Pagliarulo • May 9, 2022 -
Jacob Bell/BioPharma Dive
Clay Siegall, founding Seagen CEO, takes leave amid domestic violence accusation
The company's board is investigating the allegation, which Siegall, who has led Seattle's largest biotech for 24 years, denied. Chief Medical Officer and former Merck executive Roger Dansey was named interim CEO.
By Ben Fidler • May 9, 2022 -
Elizabeth Regan/BioPharma Dive
Argenx drug succeeds in trial, beats sales forecasts
The biotech reported positive results from a study meant to expand Vyvgart's use to another immune disorder, while sales from the drug's first quarter on the market exceeded expectations.
By Kristin Jensen • May 5, 2022 -
Getty Images: Edited by BioPharma Dive
Intercept sells international rights to liver drug in $400M deal
Advanz Pharma will obtain rights to Ocaliva outside the U.S., handing its maker an upfront payment nearly equivalent to its market value.
By Ned Pagliarulo • May 5, 2022 -
Permission granted by Biogen
Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan
Though executives claimed that inking deals and derisking research programs are priorities, analysts questioned whether any meaningful strategic changes will occur in the near term.
By Jacob Bell • May 4, 2022 -
Maddie Meyer via Getty Images
Moderna vaccine sales surpass expectations as company looks to fall boosters
The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.
By Ned Pagliarulo • May 4, 2022 -
Regeneron tries to shake off fall in COVID drug sales with first quarter earnings
Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S. revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread.
By Kristin Jensen • May 4, 2022
Previous
